Monitor trading volume and daily ATM sales disclosures in quarterly filings to gauge dilution pace. The $150M authorization represents ~20% of market cap — any material execution will pressure the stock. Watch for near-term Issuance Notices as a signal of cash burn acceleration.
Price Chart
Executive Summary
Achieve Life Sciences entered into an Open Market Sale Agreement with Jefferies LLC to establish an at-the-market (ATM) equity offering program for up to $150.0 million of common stock. Proceeds are intended to fund commercialization of cytisinicline, a Phase 3 e-cigarette cessation trial, and general corporate purposes. The filing signals potential future dilution but provides flexible access to capital for a pre-commercial biotech with a $746M market cap.
Key Facts
- Entered into Open Market Sale Agreement with Jefferies LLC for up to $150.0 million in common stock ATM offering.
- Jefferies will receive a 3.0% selling commission on gross proceeds.
- Proceeds intended for cytisinicline commercialization, Phase 3 e-cigarette cessation trial, and working capital.
- Company has no obligation to sell any shares; program is at the Company's sole discretion.
- Registration Statement on Form S-3 (File No. 333-292918) effective January 29, 2026.
Financial Impact
Up to $150.0 million in potential gross proceeds from ATM sales; Jefferies receives 3.0% commission.
Risk Factors
- Significant potential dilution if full $150M ATM is executed, representing ~20% of current market cap.
- Pre-commercial stage with no approved product revenue; cash burn may force aggressive ATM usage.
- Phase 3 e-cigarette cessation trial adds binary regulatory risk; failure would severely impair equity value.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-352229 |
| Document: achv-20260814.htm | 0001193125-26-352229 |
| Document: achv-ex5_1.htm | 0001193125-26-352229 |
| Document: 0001193125-26-352229-index-headers.html | 0001193125-26-352229 |
| Document: 0001193125-26-352229-index.html | 0001193125-26-352229 |
| Document: 0001193125-26-352229.txt | 0001193125-26-352229 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3 | $7.24 $7.19 | ▼ −0.69% | ▼ −0.27% | $6.54 (−9.67%) |
Oct 1, 2026 25d ago | 8-K | $7.24 $7.01 | ▼ −3.18% | ▼ −3.85% | $6.54 (−9.67%) |
Aug 14, 2026 10w ago | 8-K | $7.50 $7.52 | ▼ −0.27% | ▼ −0.94% | $6.54 (+12.80%) |
Aug 11, 2026 10w ago | 8-K | $6.69 $7.25 | ▲ +8.37% | ▲ +7.67% | $6.54 (−2.24%) |
Aug 11, 2026 10w ago | Press Release | $6.77 $6.69 | ▲ +1.18% | ▲ +1.43% | $6.54 (+3.40%) |
Aug 7, 2026 11w ago | Institutional Cluster | $6.65 $6.67 | ▲ +0.30% | ▲ +0.33% | $6.54 (−1.65%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.52 $5.52 | · 0.00% | ▲ +0.54% | $6.54 (−18.48%) |
Jun 2, 2026 20w ago | 8-K | $5.03 $4.92 | ▼ −2.19% | ▼ −1.49% | $6.54 (+30.02%) |
May 22, 2026 22w ago | EFFECT | $4.69 $4.56 | ▲ +2.77% | ▲ +3.36% | $6.54 (−39.45%) |
May 19, 2026 22w ago | Press Release | $4.45 $4.57 | ▲ +2.70% | ▲ +1.66% | $6.54 (+46.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers